Benzinga
19 Feb 2026, 15:21 UTC · 30w ago
Verdict
Headline takes no side. We score VTAK −0.40 across five claims — moderately bearish.
−0.40moderately bearish
More negative than 72% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Catheter Precision is divesting its atherectomy catheter technologies for a minimal $15,000 upfront cash payment.
More negative than 98% of claims this week
Catheter Precision shares were down 5.05% at $1.61, trading near their 52-week low of $1.13.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Catheter Precision shares have decreased by 75.82% over the past 12 months.
More negative than 91% of claims this week
Catheter Precision is shifting its strategic focus entirely to its high-growth electrophysiology platform.
More positive than 64% of claims this week
Catheter Precision retained a 5% equity stake in the acquiring company and a ten-year royalty agreement on net sales of the divested technologies.
More positive than 51% of claims this week
Which stocks this story touches
More negative than 72% of ticker scores this week
The company is divesting non-core assets and the stock is experiencing significant bearish technical trends and a price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
−90.7%
Price agrees with the score
$0.1586 vs $1.70 close before publication (Feb 18) · not market-adjusted
VTAK chart →
